Medtronic plc — Form 10-Q Summary
Reporting period: The filing covers the third quarter and first nine months of fiscal 2022, ended January 28, 2022. The metadata’s “2021 Q3” label does not match the filing period. Medtronic is a global medical technology company reporting four segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. Amounts below are in U.S. dollars.
Financial performance
| Metric | Three months ended Jan. 28, 2022 | Prior-year quarter | Nine months ended Jan. 28, 2022 | Prior-year nine months |
|---|---|---|---|---|
| Net sales | $7.763B | $7.775B | $23.597B | $21.929B |
| Operating profit | $1.659B | $1.277B | $4.081B | $2.879B |
| Net income attributable to Medtronic | $1.480B | $1.270B | $3.554B | $2.246B |
| Diluted GAAP EPS | $1.10 | $0.94 | $2.63 | $1.66 |
| Operating cash flow | Not separately stated for quarter | Not separately stated for quarter | $5.289B | $4.495B |
| Free cash flow (non-GAAP) | Not separately stated for quarter | Not separately stated for quarter | $4.310B | $3.517B |
Quarterly sales were essentially flat year over year; nine-month sales rose 8%. Based on reported figures, gross margin was approximately 68.3% for the quarter versus 66.3% a year earlier, and operating margin was approximately 21.4% versus 16.4%. For the nine months, those margins were approximately 68.0% versus 64.3%, and 17.3% versus 13.1%, respectively. These percentages are calculated from reported sales and costs.
Management’s non-GAAP diluted EPS was $1.37 for the quarter versus $1.29, and $4.10 for the nine months versus $2.93. These measures exclude specified items and are not substitutes for GAAP results.
Balance sheet and liquidity
- At January 28, 2022, cash and cash equivalents were $3.479B and current investments were $7.742B. Total current assets were $23.303B; current liabilities were $8.927B.
- Total debt was approximately $25.2B, down from $26.4B at April 30, 2021, primarily due to exchange-rate movements on euro-denominated notes. Cash and current investments together were approximately $11.2B.
- The company had no commercial paper outstanding and no borrowings under its $3.5B revolving credit facility; it reported compliance with facility and debt covenants.
- Nine-month dividends were $2.540B and share repurchases were $1.138B. Medtronic repurchased 8 million shares during the nine-month period and reported approximately $4.4B remaining under its authorization.
Material changes and operating trends
- Quarterly segment sales were: Cardiovascular $2.745B (+1%); Medical Surgical $2.290B (-1%); Neuroscience $2.144B (+1%); and Diabetes $584M (-7%). Nine-month sales increased in Cardiovascular (+8%), Medical Surgical (+8%), and Neuroscience (+10%), while Diabetes declined 1%.
- Management attributed the quarter’s subdued sales to Omicron-related hospital procedure disruption, particularly in the U.S., alongside supply constraints and staffing and absenteeism challenges. Nine-month growth largely reflected recovery from pandemic-affected prior-year procedure volumes.
- Other operating expense included $726M of charges in the first quarter related to the decision to stop distributing and selling the HVAD heart-assist system. The charges included $515M of noncash impairments and inventory write-downs; approximately 4,000 implanted patients remain supported.
- Research and development expense rose to $2.094B for the nine months from $1.861B, including $101M for acquired in-process research and development. Quarterly and nine-month GAAP results also reflect restructuring, litigation, amortization, and other specified items.
- Nine-month operating cash flow increased $794M year over year. Management cited higher customer collections, partly offset by higher employee payments. Investing cash use declined, while financing cash flow shifted to a $3.387B use, reflecting prior-year financing activity and higher share repurchases and dividends.
Outlook, risks, and contingencies
- The filing provides no clear quantified full-year consolidated revenue or EPS guidance. Management said future procedure volumes remain uncertain and could vary by therapy and geography with COVID-19 trends, staffing shortages, and supply disruptions.
- Other identified risks include inflation and higher labor and material costs, pricing and reimbursement pressure, competition, currency movements, regulatory delays, and potential impacts from Russia-Ukraine-related sanctions and measures.
- Medtronic expects the majority of remaining charges for its Enterprise Excellence and Simplification restructuring programs to be incurred by the end of fiscal 2022. Estimated total program costs are $1.6B–$1.8B and $400M–$450M, respectively.
- Intersect ENT’s proposed approximately $1.1B acquisition was pending antitrust clearance and was expected to close in the first quarter of fiscal 2023. Medtronic also agreed to acquire Affera for $925M, including $250M of contingent consideration, subject to closing conditions.
- Accrued litigation was approximately $0.3B. The company warns that ultimate litigation costs could differ materially from estimates. Hernia mesh claims were not accrued because losses were not considered probable or reasonably estimable. A tax dispute concerning income allocation to Puerto Rico remained subject to a pending Tax Court decision and possible appeal; gross unrecognized tax benefits were $1.7B.
- A December 2021 FDA warning letter concerning the MiniMed 600 series pump and a remote controller may limit certain U.S. Diabetes product launches until findings are resolved. The filing also discusses corrective actions and recalls affecting certain vascular products.
Important facts for investors to verify
- How procedure volumes, supply availability, and staffing conditions develop, and whether these factors affect sales and margins beyond this quarter.
- The underlying performance behind GAAP and non-GAAP EPS, including the HVAD charge, restructuring costs, tax benefits, and other adjustments.
- Progress on product corrective actions, the FDA warning letter, and regulatory approval and launch timelines for key products.
- Developments in litigation and tax matters, including potential changes to accrued liabilities or cash outflows.
- Completion timing, purchase consideration, and expected financial effects of the Intersect ENT and Affera acquisitions.